A novel neoadjuvant immunotherapy confers improved overall survival in oral cancer patients with low tumor PD-L1 expression: The IT-MATTERS Clinical trial—Prognostic role of tumor PD-L1 expression.
A three-drug immunotherapy combination cuts the risk of death by 74% in advanced mouth cancer patients with limited prior immune activation.
In locally advanced OSCC patients with cN0 and PD-L1 TPS <10%, neoadjuvant LI+CIZ+SOC vs SOC achieved OS HR 0.26 (p=0.0023) and KM log-rank p=0.0013, with 32% absolute survival advantage at 60 months and PFS HR 0.43 (p=0.0178). This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- phase 3 RCT (NCT01265849; EudraCT 2010-019952-35)
- Category
- novel_therapeutics
- Maturity
- Validated
- Journal
- Oral Oncol
Why it surfaced
Phase 3 RCT with a striking OS benefit (HR 0.26) in a PD-L1-low OSCC subgroup—a population where standard immunotherapy fails; 5-year OS data; potentially practice-changing if validated in larger cohorts; directly addresses a critical unmet need (<50% 5-year survival in LA OSCC).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.